Olaparib Tablets 150 mg (Lek Pharmaceuticals d.d.)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Olaparib Tablets 150 mg (Lek Pharmaceuticals d.d.), covering 2024-10-03 to 2024-10-03. Get the full timeline:
Most recent: Clinical Trial Update: A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer [Phase 1]